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The Interscience Conference
on Antimicrobial Agents and
Chemotherapeutics (ICAAC)
Chicago, Illinois
September 14-17, 2003
Rick Altice*, M.D.
A symposium at ICAAC entitled "Prisons
as Amplification Systems for
Infectious Diseases" covered HIV,
Hepatitis C Virus, MRSA and
tuberculosis. Other pertinent ses-
sions focused on management
issues for HIV and treatment of
HIV/HCV coinfection. What follows
are some of the highlights from this
year's conference.
Triple NRTI Therapy
In one late-breaker session, more
unfavorable data was presented
concerning the use of triple NRTI therapy. ACTG
5095 demonstrated that the fixed dose combina-
tion of AZT+3TC+ABC (Trizivir) was inferior to
the fixed dose of AZT+3TC plus EFV and inferi-
or to Trizivirplus EFV.  This study was halted
prematurely when the Trizivira m had signifi-
cantly higher failure rates, regardless of whether
the baseline viral load was above or below
100,000 copies/mL.i
Data was presented comparing two once-daily
strategies in persons who were antiretroviral
agent naive, the triple NRTI combination of
3TC+ABC+TDF (N=102) vs. 3TC+ABC+EFV
(N=92).  An unplanned interim analysis led to
discontinuation of the triple NRTI arm. Baseline
characteristics were similar in the two arms, with
a median CD4=252 and VL=4.53 log (~30,000
copies/mL).  Approximately 20% of subjects in
each arm had a baseline VL >100,000.
Compared to the EFV-containing arm, the triple
NRTI arm had a higher virologic non-response
rate (49% vs. 5.4%) and lower proportion achiev-
ing a VL <50 by 16 weeks of treatment (29% vs.
95%). For 36 of the 50 virologic non-responders
who had genotypic information available, 23
(64%) had both the K65R and M184V mutations.
Thirteen (36%) had only a M184V/I mutation.
Multiple hypotheses were proposed for this dis-
mal outcome for triple NRTI therapy. It is unlike-
ly that efficacy of the once-daily ABC+3TC is the
culprit because the EFV-containing arm per-
formed well and other studies in which ABC was
found to be effective when used once daily. A
drug interaction study demonstrated no effect of
TDF on ABC serum levelsii, however the reverse
has not yet been studied, nor
have intracellular pharmacokinet-
ics been explored. Irrespective of
the etiology, it is clear that the triple
NRTI regimen of 3TC+ABC+TDF
should not be used. These studies
provide further evidence that triple
NRTI regimens are inferior to those
containing an NNRTI or a PI, and
should generally be avoided.  
ABC Once-Daily Dosing
Data was presented further sup-
porting the use of once-daily ABC. Intracellular
levels of ABC metabolites have a half-life of over
20 hoursiii  and a placebo-controlled, randomized
trial in 770 patients receiving once-daily 3TC and
EFV with either once or twice-daily ABC demon-
strated that the regimen using once-daily ABC
was not inferior to the one where ABC was given
twice-daily. In this study, the baseline median
CD4 was 262 and the median VL was 4.9 log,
with 44% of subjects having a VL >100,000.
Overall, 67% of subjects had a VL <50 at 48
weeks (irrespective of baseline VL) with the rate
of discontinuation and ABC hypersensitivity syn-
drome (7-9%) being equivalent in both arms.
Therefore, once-daily dosing of ABC may be
safely used with the usual precautions of hyper-
sensitivity reactions.  
T-20
The full 48 weeks of data were presented on the
TORO (T-20 vs. Optimized Regimen Only)  trials
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that compared a geno/phenotype-guided
optimized background (OB) alone vs. OB+T-
20 in highly experienced HAART patients. At
48 weeks, VL <400 copies/ml was achieved
in 30% of those receiving OB+T-20 vs. 12%
of those receiving OB alone. The median
time to VL failure was 32 weeks in the T-20
arm compared to 11 weeks receiving OB
only.iv In those who received T-20, adverse
effects included injection site reactions, a
six-fold increase in the incidence of bacteri-
al pneumonia and a two-fold increase in
eosinophilia.v For patients treated with T-20,
a non-detectable VL was most likely to be
achieved if the patient had a baseline CD4
>100 cells/mm3, a  HIV VL <100,000
copies/ml, had prior use of <10 antiretrovi-
rals, and there are at least two active agents
in the OB.  
HCV in HIV-Coinfected Patients
Several studies using viral kinetic decay
curves demonstrated reduced clearance of
HCV in coinfected patients as compared to
HCV-infected individuals who were not HIV-
infected. Two studies with small sample
sizes using standard interferon therapy
found that among those patients who did not
experience a drop in HCV VL of 99% after
12 weeks of treatment, no patients achieved
a sustained viral response (SVR).vi,vii Among
those patients who did experience a 2 log
decline in HCV VL at 12 weeks, 58-66%
achieved a sustained viral response. One
worrisome outcome was that nearly 40% of
subjects who achieved an end-of-treatment
response relapsed. This finding may lend
support to a longer duration of treatment for
coinfected patients.  
One potentially significant presentation pro-
vided support for treatment with pegylated-
interferon + ribavirin (RBV) even in the
absence of early virological response at 12
weeks.  In 10 patients who failed to achieve
an end-of-treatment virological response,
liver biopsies demonstrated a decrease in
mean histological activity index (HAI) score
from 7.9 to 3.9. Although larger studies are
needed to confirm this finding, patients who
do not respond virologically may very well
benefit histologically with reduced inflamma-
tion. Hopefully, longitudinal studies will sup-
port a delay in progression to cirrhosis.viii
One HCV treatment study in HIV-infected
patients provided some information about
what not to do. This study treated 154 sub-
jects with pegylated-interferon alone for 12
weeks. If the HCV VL reduction was <2 log,
patients were randomized to receive place-
bo or the addition of RBV. The late addition
of RBV had minimal impact on the ability of
patients to achieve an SVR. The SVR of
14% is lower than seen in any other trial
involving coinfected patients and is likely
due to the lack of use of RBV at the time of
initiation with interferon therapy.ix
Report from the Central
and Eastern European
Conference on Drug
Infection Services in
Prison
Popowo, Poland
September 18-21, 2003
Thomas Kerr**, PhD.
Ralf Jürgens***, LL.M, Dr jur. 
Several countries in Central Eastern Europe
and the former Soviet Union are in the midst
of epidemics of injection drug use (IDU) and
HIV/AIDS. During Russia's transition to
democracy and a free market economy,
rates of poverty and IDU soared. As of 2001,
there were 177,000 registered cases of
HIV/AIDS in the country. Similar HIV/AIDS
epidemics have been observed in neighbor-
ing countries such as Ukraine, where
400,000 individuals are believed to be living
with HIV/AIDS. 
As IDU continues to drive the HIV/AIDS epi-
demic in Central and Eastern Europe and
the former Soviet Union, and as drug users
are over-represented in prisons, high rates
of HIV infection among prisoners are a
growing concern. In Ukraine, where 69% of
HIV infection is linked to IDU, it is estimated
that 7% of the prison population is HIV-
infected. In Latvia, 20% of HIV infections -
half of the new cases diagnosed each year -
are found among prisoners. In Poland it is
estimated that 20% of all people living with
HIV/AIDS in the country have spent time in
prison or pre-trial detention.  In a two-week
period in Lithuania in May of 2002, the num-
ber of new HIV-positive test results among
prisoners equaled the entire number of
cases of HIV previously identified in the
entire country.  Between May and August of
2002, 284 prisoners (15% of the total
Lithuanian prison population) were diag-
nosed as HIV-infected. 
As in North American settings, illicit drug use
persists in prisons in Central and Eastern
Europe and former Soviet Union despite
considerable efforts to prevent the entry of
these drugs. However, prison authorities in
these countries are following a global trend
by recognizing the importance of health ser-
vices that address drug-related harm,
including harm reduction programs such as
peer outreach, methadone maintenance
therapy, and needle exchange. 
In September 2003, the Central and Eastern
European Network of Drug Services in
Prison (CEENDSP), in partnership with the
European Commission, the Open Society,
and the Polish Prison System, hosted the
conference "Dealing with Drug Use in
Prison: Reviewing the European Experience
and Sharing Good Practice." Created in
January of 2003, the CEENDSP network
aims to assist with the development of effec-
tive drug services in Central and Eastern
European prisons through the dissemination
of information, expertise and knowledge.
The conference afforded participants oppor-
tunities to discuss challenges associated
with drug use and HIV/AIDS in prisons, and
to learn from the many success stories in
the region. Panel discussions focused on an
array of issues confronting prison systems,
such as meeting the principle of equivalence
(i.e. ensuring equal levels of health care
delivery in the community and prisons), and
increasing collaboration between non-gov-
ernmental organizations and prison sys-
tems. In addition, participants gleaned infor-
mation on new developments in prison
health services, including the implementa-
tion of methadone and needle exchanges
programs (NEP) within correctional facilities. 
Needle Exchange Programs
NEPs have long existed in community set-
tings, and independent evaluations have led
to endorsements of NEPs by the U.S.
National Institutes of Health Consensus
Panel, U.S. National Research Counsel,
American Public Health Association, the
American Medical Association, the World
Health Organization, the U.S. National
Academy of Sciences, among others.  In
ecent years, NEPs have been implemented
in various correctional settings, including
both men's and women's facilities.  While
many prison-based NEPs were initially
implemented on a pilot basis, there has
been a growing acceptance of these initia-
tives, and the number of NEPs in prisons
has increased steadily. NEPS now exist in
prisons in Switzerland, Belarus, Germany,
Spain, Moldova, and Kyrgyzstan. In the past
year alone, the number of prison-based
NEPs in Kyrgyzstan increased from one to
11. Methods used to distribute syringes in
prisons have included dispensing machines
and distribution by health care staff, commu-
nity agencies, or peers trained to provide
outreach services. 
Scientific evaluations have consistently
shown that the provision of syringes in
p ison does not lead to increases in drug
consumption, injecting, or improper syringe
di posal. Moreover, these studies have not
documented that syringes have been used
as weapons. Syringe sharing and new
cases of HIV and hepatitis have decreased
2
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Dear HEPP subscriber: 
In 1988, the World Health Organization established World AIDS Day to focus global atten-
tion on HIV/AIDS. Although there have been some successes, 15 years later the pandem-
ic continues to spread virtually unabated in much of the developing world.  
Tragically, techniques known to be effective in slowing the spread of HIV are too often
underutilized. Funding for proven HIV prevention strategies such as condoms and needle
exchange often becomes bogged down in moralistic wrangling. Both within the correctional
environment and beyond, homophobia and laws regulating consensual sexual activities can
function to deter at-risk individuals from being tested, utilizing effective prevention tech-
niques, and seeking HIV treatment.  
Stigmas associated with addiction and illicit drug use also result in policies that limit effec-
tive prevention. Inadequate resources allocated to drug treatment and harm reduction
strategies create a Hobson’s choice, increasing the likelihood that many of those incarcer-
ated for drug-related crimes will never break free from the cycle of addiction and incarcera-
tion. The sexual partners of those with ongoing HIV/hepatitis risk behaviors are also vul-
nerable, as are children born to mothers who acquire HIV through sharing needles or hav-
ing unprotected sex with an at-risk partner.  
The Centers for Disease Control and Prevention (CDCP) have set a number of straightfor-
ward goals for this nation’s approach to the HIV/AIDS epidemic. Among them are: (1)
Decreasing the number of persons at high risk for acquiring or transmitting HIV by deliver-
ing targeted, sustained and evidence-based HIV prevention interventions, (2) Through vol-
untary testing, increasing the proportion of HIV-infected people who know they are infected,
(3) Increasing the proportion of HIV-infected people who are linked to prevention, care and
treatment services, and (4) Strengthening the capacity to monitor the epidemic.
What better place to implement these goals than in jails and prisons?  As correctional health
care providers, we know firsthand that our patients represent the largest group of HIV-infect-
ed and at-risk individuals. In our ongoing effort to provide a forum to address the HIV pre-
vention, diagnosis, and treatment needs of this nation, this month's issue of HEPP Report
brings you our Fall 2003 Conference Update. Next month will feature a comprehensive
review of the management of end stage liver disease, a spotlight on the growing problem of
methicillin resistant Staphylococcus aureus (MRSA) in the correctional setting, and high-
lights from the annual American Association for the Study of Liver Diseases meeting.  
Sincerely,
Joseph Bick, M.D.
Letter from the Editor
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4in prisons where NEPs have been imple-
mented. 
There is still more work to be done in
addressing drug-related harm in correctional
facilities.  However, significant steps are
being taken to meet the World Health
Organization's Guidelines on HIV Infection
and AIDS in Prisons, which state: "All pris-
oners have the right to receive health care,
including preventative measures, equivalent
to that available in the community without
discrimination."  The examples given at the
CEENDSP conference in Popowo confirm
that the implementation of harm reduction
programs, such as NEPs, can be achieved
in a variety of settings, including prisons.
Hopefully, these success stories will help to
inform the delivery of prison-based health
care throughout the world. 
The National 
Commission on Correctional 
Health Care (NCCHC)
PreColloquium: 
Managing Infectious and
Contagious Diseases in the
Correctional Setting
Austin, Texas
October 4-8, 2003
Julia Noguchi, MA
On October 4, 2003 an expert panel opened
the fall meeting of the NCCHC with a collo-
quium sponsored by HEPP Report and the
Brown University AIDS Program. Dr. Joseph
Bick of the California Department of
Corrections and Dr. Anne De Groot of Brown
University engaged the audience with a live-
ly discussion on MRSA, SARS, smallpox,
anthrax and tuberculosis, which are just a
few examples of diseases caused by trans-
missible agents that can rapidly spread in
congregate living environments. Dr. Bick fol-
lowed with a comprehensive update on HIV-
management.
Dr. Karl Brown, Infectious Diseases
Supervisor at Rikers Island jail in New York
City, gave an in-depth overview of sexually
transmitted diseases (STDs). Using a case
study of a patient with syphilis as a platform
for his discussion, Dr. Brown focused on
screening and treatment of STDs. STDs,
though highly prevalent in the correctional
setting, often go untreated since patients
may be unaware of their infection. This can
have serious implications as STDs cause
significant morbidity and can increase the
risk of HIV acquisition and transmission.
Diagnosis of STDs is usually made based on
history and symptoms at presentation.
Infection can usually be confirmed with lab
studies, such as inexpensive urine tests that
can diagnose gonorrhea and clamydia.
Effective treatments are available for most
STDs. 
Dr. Cindy Weinbaum of the CDC and Dr.
Brian Pearlman of the Atlanta Medical
Center covered viral hepatitis from A to C.
While Dr. Pearlman addressed natural histo-
ry, treatment and side effects, Dr. Weinbaum
honed in on prevention and control in the
correctional setting. Some important facts to
bear in mind: the higher prevalence of
chronic HBV in U.S. jails and prisons (2%),
compared to that in the U.S. general popula-
tion, (0.5%); 20-40% of inmates are HCV-
infected versus 1-2% in the U.S. general
population; illicit drug use remains the pri-
mary mode of transmission of HBV and
HCV, with 18% of jail inmates reporting
injection drug use (IDU). Dr. Weinbaum also
reviewed long-term complications of hepati-
tis, noting that HCV is now  the most com-
mon cause of liver transplantation in the
U.S.  Dr. David Thomas of the Nova
Southeastern University College of
Osteopathic Medicine concluded with a
cogent summary peppered with enough wit
to last us until May 2004, when NCCHC's
spring meeting will convene in Chicago.
The 41st Annual Meeting
of the Infectious Disease
Society of America (IDSA)
October 9-12, 2003
David Alain Wohl****, M.D.
Infectious disease specialists from around
the world convened in San Diego to attend
symposia, oral presentations and poster
sessions on diverse infectious diseases-
related issues.  This year the usual fare of
lyme disease, HIV, tuberculosis and infec-
tion control had to compete for attention with
SARS, bioterrorism, and multidrug bacterial
resistance.
The IDSA conference serves as an opportu-
nity for the presentation of new data, as well
as for clinical reviews.  As there are now
numerous other conferences dedicated to
HIV and to HCV, not much new was pre-
sented at IDSA on these infections.
However, there were a few notable presen-
tations highlighted below that are relevant to
correctional HIV care. In addition, there were
some wonderful overviews, including a rivet-
ing discussion of perinatal HIV transmission
by Cathy Wilfret, M.D. of the Elizabeth
Glaser Foundation and a "top ten" list of
HIV-related publications in 2003 by Bill
Powderly, MD of Washington University.
Audio and video tapes can be ordered at
http://www.idsociety.org/me/
am2003/toc.htm.
HAART Works in Prison
In a poster presentation of significant inter-
e  to HEPP readers, Sandra Springer of
Yale University and her colleagues conduct-
ed a retrospective review of Connecticut
Department of Corrections' prison inmate
records from 1997-2002 to gauge the effec-
tiveness of combination antiretroviral thera-
pies in prison (abstract 665).  Over 1,000
HIV-infected inmates receiving HAART for at
least six months were studied.  More than
80% were male and half were African-
American. The overwhelming majority had a
history of substance abuse, the mean age
was 39 years, and the average time in prison
was 478 days. Ninety-eight percent of
inmates receiving HAART were prescribed
therapy in accordance with Department of
Health and Human Services (DHHS) guide-
lines; an impressive 57% had an HIV VL
below the limits of detection during their
incarceration.  Forty-six percent were receiv-
ing a PI-containing regimen, 32% were on
an NNRTI, 8% were receiving a PI + NNRTI,
nd 14% were on only NRTIs. There was
considerable modification of HAART during
the study period across all regimen types.  
The authors also examined the change in
CD4+ cell count and HIV viral load among
those inmates who were released and re-
incarcerated.  The benefits of HAART during
incarceration were largely lost during the
period of release, with a mean decrease in
CD4 count of -81/uL and an increase in viral
load of +1.57 log. This study provides a
message that is double-edged: HIV-infected
inmate patients respond well to antiretroviral
therapy while incarcerated; however, the
benefits of treatment often evaporate follow-
ing release. The challenge to maintain in-
prison gains following release into the free
world is clear as data accumulate indicating
that post-release, many HIV-infected per-
sons fare poorly.  
DOT-on-Wheels
Dr. Rick Altice presented results from a ran-
domized controlled trial of modified directly
observed therapy (DOT) vs. self-adminis-
tered therapy (SAT) of HIV medications
among urban HIV-infected substance
abusers (abstract 652). Subjects assigned to
DOT had all medications pre-packaged into
dose packs that were then delivered to five
sites around New Haven, Connecticut by a
mobile community health van for patient
pick-up. Subjects were usually observed
either taking their meds or given packs to
take with them if observation was not possi-
b e. In addition, these subjects received a
programmable pager that reminded them to
meet the van, go to medical appointments
and take medications. Of the 112 subjects
Fall Conference
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5randomized, two-thirds were male, 58%
were African-American, 30% used cocaine,
65% used both cocaine and heroin and 31%
were homeless. Almost three-quarters had
depression based on screening exam.
Median CD4+ cell count was 249/uL and the
median viral load was 142,000 copies/mL.  
At six months, those randomized to the DOT
program had a greater increase in CD4+ cell
count (112/uL versus 11/uL), more signifi-
cant reduction in viral load (-1.71 log versus
-0.46 log) and much better self-reported
adherence. These results demonstrate the
success of a novel and aggressive adher-
ence program tailored to meet the needs of
a hard-to-reach population.  The appeal of
applying this intervention to released former
inmates is obvious, especially in light of the
findings of the previously described study.  
Acute HCV Among Prisoners
In another report from New England, Alysee
Wurcel and colleagues described their
efforts to identify acutely HCV-infected
prison inmates in Massachusetts (abstract
592). The authors developed a program
which evaluated inmates with <1 year histo-
ry of injection drug use (IDU) who developed
elevated liver transaminases. Over a period
of 18 months, 15 patients were identified as
having acute HCV (11 women, 10
Caucasian, 5 Latino).  Most (11) had defini-
tive recent HCV as evidenced by document-
ed seroconversion or a known prior negative
HCV serology. The remaining four patients
were considered to have probable recent
HCV infection based on development of clin-
ical jaundice and elevated transaminases in
the absence of evidence of prior HBV or
HAV infection. This report highlights the
opportunity for disease detection within cor-
rectional facilities. The authors recommend
HCV testing of all inmates with recent initia-
tion of IDU and elevated liver transaminas-
es. It should be noted that other correctional
infectious disease experts recommend that
all prison inmates should be screened for
HCV, given its extremely high prevalence in
the nation's prisons.
HIV/HCV Co-infection and Mental Illness
Dina Hooshyar in North Carolina conducted
an interesting retrospective review on the
prevalence of mental illness and substance
abuse among HIV-infected patients attend-
ing a university infectious diseases clinic
where a standardized mental health and illic-
it drug use screen is administered to all
patients (abstract 618). Among the 1,018
patients), 33% women, 63% African-
American), 209 (20.5%) were HCV-co-
infected. A comparison of those who were
HCV seropositive versus those who were
HCV seronegative revealed that co-infected
patients had lower CD4+ cell counts (292/uL
versus 386/uL, p=0.001), a higher preva-
lence of psychiatric diagnoses such as
depression and anxiety or panic disorders
(68% versus 58%, p=0.014) and substance
abuse (48% versus 30%, p<0.0001).  In a
regression analysis adjusting for gender,
race, CD4+ cell count, viral load, HCV-
infected patients were almost twice as likely
to have a psychiatric diagnosis (OR=1.8
[95% CI, 1.3, 2.5]) and had more than dou-
ble the risk of substance abuse (OR=2.2
[95% CI, 1.5, 3.2]).  These results indicate
that screening for mental illness and sub-
stance abuse is a must for all HIV-infected
persons, especially those with HCV. Further,
these data are ominous given the aversion
of many providers to prescribe HCV therapy
to those with significant mental illness.  
Isolated HBV Core Seropositivity - Is it
Significant?
HBV serologies, the bane of most medical
students, are commonly misunderstood.
Those who routinely order the tests know
that it is not uncommon to come across a
patient with HIV infection who has isolated
IgG anti-HBc but no HBV surface antigen
(HBsAg) or surface antibody (HBsAb). The
significance of this result has been debated.
To help clear the air, Janel Dockter and her
group in Boston tested HIV-infected patients
known to be HBsAg and HBsAb negative for
a y evidence of IgG anti-HBc (abstract 601).
In addition, these patients were also tested
for HBV viral load.  Of the 90 patients tested,
48 (53%) were IgG anti-HBc seropositive.
Interestingly, patients also infected with HCV
w re more likely to have isolated anti-HBc
than those without HCV (85% versus 28%,
p<0.001).  CD4+ cell count did not seem to
play a role in isolated anti-HBc. HBV DNA
PCR detected virus in only one of the 48
subjects with isolated anti-HBc.  
The study demonstrates that persons with
HIV and HCV co-infection who do not have
evidence of HBV infection by HBsAg and
HBsAb testing will frequently have isolated
anti-HBc. Such patients are also rarely
viremic. There is debate as to whether those
with isolated HBc Ab should be vaccinated.
This isolated core probably represents loss
of HbsAb. 
Conclusion
Despite the emergence of new infectious
diseases challenges, HIV and HCV contin-
ued to be a major focus at IDSA.  Although
little new data was presented, there were
some interesting results that will help
providers in correctional facilities better
understand and manage HIV.  Unfortunately,
the high prevalence of HIV and HCV within
correctional settings did not translate into a
major focus on correctional HIV/HCV issues.
O e can hope that future conferences will
include more research from prisons and
jails, better reflecting the significant role that
correctional health care professionals play in
this nation's management of these diseases.  
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VACCINE
Tetanus
diphtheria (Td)
Influenza
Pneumococcal
(polysaccharide)
Hepatitis B
Hepatitis A
Measles,
Mumps, Rubella
(MMR)
Varicella
Meningococcal
AGE GROUP (yrs.)
50-6419-49
1 dose booster every 10 years.
1 dose
1 dose annually
>65
HIV 101: Adult Immunization Schedule 
The following are recommended as a standard of care.
FIGURE 1: Recommended Adult Immunization Schedule by age group
– United States, 2003-2004*
1 dose annually
1 dose
3 doses (0,1-2,4-6 months)
2 doses (0,6-12 months)
1 dose
For persons with medical/
exposure indications
Catch-up on childhood
vaccinations
1 dose if MMR vacci-
nation history is unre-
liable; 2 dose for per-
sons with occupation-
al or other indications.
2 doses (0,4-8 weeks) for persons who are susceptible
MEDICAL CONDITION
Pregnancy
Diabetes, heart disease,
chronic pulmonary disease,
and chronic liver disease,
including chronic alcoholism
Congenital immunodeficien-
cy, leukemia, lymphoma,
generalized malignancy,
therapy with alkylating
agents, antimetabolites,
radiation, or large amounts
of corticosteroids
Renal failure/end-stage
renal disease and patients
receiving hemodialysis or
clotting factor concentrates
Asplenia, including elective
splenectomy and terminal
complement-component
deficiencies
Human immunodeficiency
virus (HIV) infection
VACCINE
Tetanus-
diphtheria (Td)
Influenza
FIGURE 2: Recommended Adult Immunization Schedule by medical 
condition – United States, 2003-2004*
For all persons in
this age group
For all persons in this
group.
For persons with medical/
exposure indications
Catch-up on childhood vaccinations Contraindicated
Pneumococcal
(polysaccharide) Hepatitis B Hepatitis A
Measles, mumps,
rubella (MMR)
Varicella
A
B C D
E
E
H E,I,J
E,K L
G
*Notice to Readers: “Recommended Adult Immunization Schedule -- UnitedStates, 2003-2004". MMWR. 10 October, 2003 /  52(40); 965-969. Available
at www.cdc.gov/mmwr/preview/mmwrhtml/mm5240a6.htm. Please visit website for additional references for Figures 1 and 2.
FIGURE 2: References
A. For women without chronic diseases/conditions,
vaccinate if pregnancy will be at second or third
trimester during influenza season. For women with
chronic diseases/conditions, vaccinate at any time
during the pregnancy.
B. Although chronic liver disease and alcoholism
are not indicator conditions for influenza vaccina-
tion, administer 1 dose annually if the patient is
aged >50 years, has other indications for influenza
vaccine, or requests vaccination.
C. Asthma is another indicator condition for influen-
za but not for pneumococcal vaccination.
D. For all persons with chronic liver disease.
E. For persons aged <65 years, revaccinate once
after 5 years have elapsed since initial vaccination.
F. Persons with impaired humoral but not cellular
immunity may be vaccinated.
G. For hemodialysis patients use special formula-
tion of vaccine (40 mg/mL) or two 1.0 mL 20 micro-
gram doses administered at one site. Vaccinate
early in the course of renal disease. Assess anti-
body titers to hepatitis B surface antigen (anti-HBs)
levels annually. Administer additional doses if anti-
HBs levels decline to <10 mlU/mL.
H. No data have been reported specifically on risk
for severe or complicated influenza infections
among persons with asplenia. However, influenza
is a risk factor for secondary bacterial infections
that might cause severe disease in asplenics.
I. Administer meningococcal vaccine and consider
Haemophilus influenzae type b vaccine.
J. In the event of elective splenectomy, vaccinate
>2 weeks before surgery.
K. Vaccinate as close to diagnosis as possible
when CD4 cell counts are highest.
L. Withhold MMR or other measles-containing 
vaccines from HIV-infected persons with evidence
of severe immunosuppression. 
HIV/Hepatitis C Co-infection:
Your Future, Your Choices 
November 21, 2003 
Four Points Sheraton at 
Denver University - Denver, CO 
Contact: NATAP: 580 Broadway,
Ste 1010, New York, NY 10012
Call: 212.219.0106
Fax: 212.219.8473
Email: info@natap.org
Visit: www.natap.org. 
The workshop is free of charge. 
Advanced Course in
Antiretroviral Therapy: From
Laboratory to Patient  
November 21-22, 2003
New York, NY 
The agenda comprises topics of
high relevance to modern clinicians.
Attendees will have the opportunity
to discuss these topics with opinion
leaders in the field. 
Contact:els.vanderwoude@
vironet.com
Visit: www.virology-education.com
Inside and Out: 
HIV and Corrections
December 5, 2003
Radisson Hotel
Marlborough, MA 
A conference to increase knowl-
edge, awareness, and understand-
ing of HIV infection in correctional
and post-correctional settings. 
Contact: Andy Diamond
Call: 617.450.1264
Fax: 617.437.6445
Email: adiamond@aac.org
Harm Reduction Training
Institute 
December 12, 2003 
New York, NY 
This one-day training program will
demonstrate and discuss tech-
niques for working with crack users. 
Call: Emily at 212.683.2334 Ext. 18
Fax: 212.213.6582
Email: hrc@harmreduction.org
Visit: www.harmreduction.org 
The 11th Conference on
Retroviruses and 
Opportunistic Infection
February 8-11, 2004
San Francisco, CA
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
Save the 
Dates
7
Study: Durability and potency of Kaletra
The 43rd Interscience Conference on
Antimicrobial Agents and Chemotherapy
(ICCAC) held September 13-17, 2003 featured a
poster (#-H-844) by Abbott on a five-year follow-
up of Kaletra (Lopinavir/ritonavir) in antiretroviral-
naïve HIV-infected patients. This was the first trial
of LPV/r in HIV-infected patients, therefore pro-
viding the longest duration of follow-up for
patients treated with LPV/r. This poster presents
data on antiviral activity, immunologic parameters
and safety through five years of follow-up.
Antiretroviral-naïve patients receiving Kaletra
exhibited sustained virologic response, with 67%
of patients demonstrating HIV RNA <400
copies/mL and 64% demonstrating HIV RNA <50
copies/mL by intent-to-treat (NC=F) analysis.
Through 252 weeks of follow-up, no protease
inhibitor resistance mutations have been
observed in subjects with sustained viral load
rebound. Discontinuations due to LPV/r-related
adverse events were 10/100, 10%.
www.natap.org, 9/27/03
Study: The Use of T-1249 (second generation
fusion inhibitor) on Patients with T-20
Resistance
Final results were reported at ICCAC on the use
of T-1249 on 51 patients with T-20 resistance.
After 11 days, HIV viral load was decreased by a
median of -1.26 log (ITT). Seventy-three percent
of patients after 11 days had at least a one log
reduction in viral load. Patients did not respond
as well if they had remained on T-20 for a long
period of time with dectectable HIV. Twenty-one
out of 25 patients who remained on T-20 for less
than 65 weeks with detectable viral load of >5000
copies/ml achieved at least a one log reduction in
viral load. Sixteen out of 26 patients who
remained on T-20 for greater than 65 weeks with
detectable viral load of >5000 copies/ml achieved
a one log reduction or greater in viral load. T-
1249 was well-tolerated and exhibited potent
short-term antiviral activity. Sixty-four percent of
patients experienced injection site reactions. The
study authors reported that baseline T-1249 sus-
ceptibility does not appear to predict short-term
responses to T-1249. 
www.natap.org, 9/27/03
Study: Effect of Short-Term Monotherapy
with UK-427,857 (first HIV attachment
inhibitor) on Viral Load in HIV-Infected
Patients
Fatkentheuer and colleagues reported for the first
time results from a one-day study of monothera-
py of the first HIV attachment inhibitor to be stud-
ied in HIV-infected patients. After HIV binds to the
CD4 receptor on the CD4 cell, HIV binds to a co-
receptor. CCR5 or CXCR4 are the two co-recep-
tors that HIV uses to attach itself to the CD4 cell
for entry into the CD4 cell, where HIV replication
takes place. "427" is the first attachment inhibitor
targeting inhibition of the CCR5 co-receptor to be
studied in HIV-infected patients. The drug is
active against HIV resistant to current HIV drugs.
Efficacy against HIV with T-20 resistance has yet
to be tested, but future studies are planned.
www.natap.org, 9/27/03
Drug Warning from the AETC National
Resource Center: Early Virologic Failure in
Patients treated with Didanosine +
Lamivudine + Tenofovir
Susa Coffey, M.D.
Gilead Sciences has issued a "Dear Health Care
Professional" letter to warn of high rates of early
virologic failure in patients treated with a once-
daily triple nucleoside reverse transcriptase
inhibitor (NRTI) regimen consisting of didanosine
+ lamivudine + tenofovir. The letter describes
interim results of a pilot study of didanosine
(enteric-coated formulation, 250 mg) + lamivu-
dine (300 mg) + tenofovir (300 mg), all dosed
once daily in 24 treatment-naïve patients. At
week 12, virologic failure (<2 log10 reduction in
HIV RNA) was seen in 91% of study subjects.
Resistance testing performed on 21 patients
revealed the M184I/V mutation in 95%, and K65R
+ M184I/V mutations in 50%. Study enrollment
was terminated upon discovery of this high rate of
early regimen failure. This announcement rein-
forces data on high rates of early virologic failure
and early emergence of NRTI-associated resis-
tance mutations that were previously reported in
several studies of other triple-NRTI regimens.
These include reports on the combinations aba-
cavir + lamivudine + tenofovir, abacavir + lamivu-
dine + zidovudine, and abacavir + didanosine +
stavudine. The combination of didanosine +
lamivudine + tenofovir, like the other triple-NRTI
regimens with demonstrated high failure rates,
are not recommended for the treatment of
patients with HIV infection. The letter is available
on the U.S. Food and Drug Administration 
website. 
http://www.fda.gov/oashi/aids/new.html,10/14/03
Inside News
Immunization Resources
Information on viral Hepatitis A:
www.cdc.gov/ncidod/diseases/hepatitis/
a/index.htm
Information on flu season - 2003-2004
www.cdc.gov/nip/flu/
Integrating Hepatitis B Vaccination into STD
and HIV/AIDS Programs:
www.cdc.gov/ncidod/diseases/hepatitis/
spotlights/integration.htm
The CDC’s National Vaccine Program Office:
www.cdc.gov/od/nvpo/pubs/adult4.htm
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through June 30,2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The most recent update of the NIH HIV treatment guidelines
states that triple NRTI regimens are as potent as both protease
inhibitor and non nucleoside reverse transcriptase inhibitor based
regimens:
a) True
b) False
2. For patients beginning a new regimen which includes T-20, an
undetectable VL is more likely to be achieved if:
a) The baseline CD4 is <100, the HIV viral load is <10,000, 
there has been prior use of <10 antiretrovirals, and there is 
at least one active agent in the new regimen
b) The baseline CD4 is >100, the HIV viral load is >100,000, 
there has been prior use of <10 antiretrovirals, and there are 
at least three active agents in the new regimen
c) The baseline CD4 is >100, the HIV VL is <100,000, there 
has been prior use of <10 antiretrovirals, and there are at 
least two active agents in the new regimen
3. Health services that may help to reduce drug-related harm in
prisons are:
a) Peer outreach programs
b) Methadone maintenance therapy
c) Needle exchange programs
d) All of the above
4. Scientific evaluations have shown that distributing needles in
prisons:
a) Usually leads to increased illicit drug consumption
b) Is unlikely to result in prisoners using syringes used 
as weapons 
c) Commonly leads to improper syringe disposal
d) Increases the incidence of needle sharing
5. Needle exchange programs in prisons are currently in operation
in:
a) France, Spain, Italy, Portugal, Holland, and Sweden 
b) Chile, Argentina, Brazil, Peru, the Falklands, and Panama
c) Switzerland, Germany, Spain, Moldova, Belarus, and 
Kyrgyzstan
d) All countries of the former Soviet Union
6. Data supports once a day dosing for all of the following antiretro-
viral agents except:
a) abacavir (Ziagen)
b) tenofovir (Viread)
c) didanosine (ddI, Videx)
d) azidothymidine (AZT)
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
8November 2003     Volume 6, Issue 11visit HEPP Report online at www.hivcorrections.org
